A Phase 1b, Open-Label, Single Dose Study Assessing the Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 21 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Casirivimab/imdevimab (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacokinetics
Sponsors Regeneron Pharmaceuticals

Most Recent Events

26 Jul 2022 Status changed from active, no longer recruiting to discontinued due to SARS-CoV-2 variants impacting susceptibility to study drug.
03 Feb 2022 Planned End Date changed from 9 Jun 2023 to 15 Jun 2022.
03 Feb 2022 Planned primary completion date changed from 9 Jun 2023 to 15 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight